Login to Your Account

Clinic Roundup

Monday, October 31, 2011

• Halozyme Therapeutics Inc., of San Diego, reported positive results from a study in patients with Type I diabetes that receive their insulin therapy via pumps. The Phase Ib randomized, double-blind, crossover design study is intended to determine insulin pharmacokinetics, glucodynamics, safety and tolerability of rHuPH20 (recombinant human hyaluronidase) as a single injection prior to the start of three days of NovoLog insulin aspart pump infusion therapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription